December 9, 2021 11:00 AM EST
News Briefing

To­tus pulls in $40M Se­ries A with sights on PI3Kα; FDA asks Sesen for an­oth­er tri­al af­ter CRL, biotech says

John Carroll

Editor & Founder

Max Gelman

Senior Editor

Paul Schloesser

Associate Editor

Af­ter spend­ing the last 18 months work­ing on iden­ti­fy­ing a lead can­cer drug, biotech start­up To­tus Med­i­cines has now raised

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

A service from the Financial Times